I'm surprised no one has made this....

[FUE2014]

A 5% minoxidil and 1% or 2% keto foam in one.

 

If you google Extina you will see there is a 2% keto foam, could be worth trying in addition to the minox foam.

[wazaam]

Interesting. I wonder if this will have the same potential benefits as the 2% shampoo?

 

Here is some additional info & ingredients on the foam;

 

Extina (ketoconazole foam, 2%) Foam contains 2% ketoconazole USP, an antifungal agent, in a thermolabile hydroethanolic foam for topical application. The chemical name for ketoconazole is piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl) -2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- with the molecular formula C26H28Cl2N4O4 and a molecular weight of 531.43. The following is the chemical structure:

Extina (ketoconazole foam, 2%) Foam contains 20 mg ketoconazole USP per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol NF, citric acid USP, ethanol (denatured with tert-butyl alcohol and brucine sulfate) 58%, polysorbate 60 NF, potassium citrate USP, propylene glycol USP, purified water USP, and stearyl alcohol NF pressurized with a hydrocarbon (propane/butane) propellant.

[FUE2014]

CORAL GABLES, Fla., July 17 /PRNewswire/ -- Stiefel Laboratories, Inc.

today announced that the U.S. Food and Drug Administration (FDA) has

approved its new drug application for Extina® (ketoconazole) Foam, 2% for

the treatment of seborrheic dermatitis. The approval, which the company

received June 12, clears the way for the product to be sold and marketed in

the United States.

Different from other treatments for seborrheic dermatitis, which

contain ketoconazole 2% in a cream, gel or shampoo vehicle, Extina is

administered using VersaFoam® HF® (hydroethanolic formulation)

technology, a unique, versatile topical drug delivery vehicle that is

quickly absorbed into the skin. Extina Foam proved to be superior to

placebo foam in a Phase III clinical trial. Of subjects receiving Extina

® Foam, 56% achieved treatment success based on an Investigator Global

Assessment compared to 42% of subjects receiving vehicle foam. Stiefel

Laboratories, the world's largest independent pharmaceutical company

specializing in dermatology, acquired the proprietary VersaFoam HF

technology with its December 2006 acquisition of Connetics Corporation.

"We are very pleased with the robust data obtained in the pivotal Phase

III clinical trial evaluating the safety and efficacy of Extina," said Jim

Hartman, Senior Vice President, U.S. Commercial Operations for Stiefel

Laboratories. "It is exciting that this product, combining the proven

efficacy of ketoconazole 2% in the patient-preferred foam delivery system

will soon be available for patients with seborrheic dermatitis. It will

provide dermatologists and other allied health professionals with an

additional treatment option for this condition and allow patients to choose

their preferred drug delivery method.

"Extina is representative of the robust and innovative product pipeline

at Stiefel Laboratories," Hartman added.

Stiefel Laboratories plans to launch the product, which will be

available only by prescription, later this year.

Extina® (ketoconazole) Foam, 2% is indicated for the topical

treatment of seborrheic dermatitis in immunocompetent patients 12 years of

age and older. Extina should be applied to the affected skin areas twice a

day (morning and evening) for four weeks. Extina is administered via

VersaFoam HF, which studies show offers consistent skin permeation, drug

distribution and drug delivery. Additional patient benefits include

versatility (Extina can be used on hair bearing and non hair-bearing skin),

it absorbs quickly and it is non-drying with no residue. For more information about Extina, please visit Extina.